Table 3.
Antipsychotic polypharmacy combinations by treatment family in patients diagnosed with schizophrenia: 2008–2015
| Polypharmacy combinations | N (% of total) | Subjects % | Time % |
|---|---|---|---|
| OA-2nd generation | 18,241 (27.5) | 38.1 | 16.2 |
| OA-2nd generation + LAI-2nd generation | 16,188 (24.4) | 26.0 | 12.7 |
| OA-1st generation + OA-2nd generation | 10,271 (15.5) | 21.1 | 7.9 |
| OA-1st generation + OA-2nd generation + LAI-2nd generation | 4213 (6.3) | 7.5 | 2.4 |
| Othera + OA-2nd generation | 3899 (5.9) | 7.9 | 3.1 |
| LAI-1st generation + OA-2nd generation | 3325 (5.0) | 7.6 | 3.1 |
| Other combinations | 10,281 (15.5) | 31.8 | 6.3 |
Abbreviations: OA Oral antipsychotic, LAI Long-acting injection antipsychotics
aOther family treatments different to OA and LAI
Subjects (%), percentage of subjects ever treated with each polypharmacy combination during the study period
Time (%) represents the percentage of time, of the total study period, during which each combination has been used
For each family, two or more concomitant treatments can be included